Microglial activation in presymptomatic Huntington's disease gene carriers.
about
The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disordersTranslocator protein 18 kDa (TSPO): molecular sensor of brain injury and repairThe P42 peptide and Peptide-based therapies for Huntington's diseaseCurrent status of PET imaging in Huntington's diseaseNeural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challengesKynurenine 3-Monooxygenase: An Influential Mediator of NeuropathologyThe choreography of neuroinflammation in Huntington's diseaseKynurenines in the mammalian brain: when physiology meets pathologyMutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 miceLaquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's diseaseDoes neuroinflammation fan the flame in neurodegenerative diseases?Neuroimaging biomarkers of neurodegenerative diseases and dementiaNeuroimmunology of Huntington's Disease: Revisiting Evidence from Human StudiesIn vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's diseaseThe ubiquitin proteasome system in glia and its role in neurodegenerative diseasesHuntington’s disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer’s diseaseMolecular Imaging Markers to Track Huntington’s Disease PathologyImprovement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease.Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease miceMutant huntingtin impairs immune cell migration in Huntington disease.Neuroimaging in Huntington's disease.IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin.Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's diseaseTranslocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative DiseasesAngiotensins and Huntington's Disease: A Study on Immortalized Progenitor Striatal Cell Lines.Serum levels of a subset of cytokines show high interindividual variability and are not altered in rats transgenic for Huntington´s diseaseMicroglial Activation in the Pathogenesis of Huntington's Disease.Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players.Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factorsAbnormal peripheral chemokine profile in Huntington's diseaseThe role of microglia in human disease: therapeutic tool or target?Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's diseaseThe endocannabinoid system as a target for the treatment of neurodegenerative disease.Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease.A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's diseaseCocaine induces nuclear export and degradation of neuronal retinoid X receptor-γ via a TNF-α/JNK- mediated mechanism.An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease.The role of the immune system in triplet repeat expansion diseases
P2860
Q24641816-A9C44A6B-10FA-4D3D-983E-B2BE1C0022EBQ24644752-8D26ABE9-A6DD-49CB-8B0D-73243A6FE0FFQ26764930-D66BE8C5-FB18-4B7F-AB53-3E0DCE9EDB2FQ26768644-C791CDEC-7BA5-450B-9029-58D01B4AAFEBQ26775932-1C63A1BE-693B-4AC8-A2DD-2105F9F536D4Q26782867-FCC51C8D-3C5C-48E3-9C8E-1D5399455864Q26828403-D70B2486-7017-4664-903C-93F1C0BE2F4AQ27003296-FA82007E-6C42-4F63-B436-35CD2BF8CBDFQ27305680-2BFCEBC9-04E8-4DAD-B6B3-19D1C2E65E85Q27316866-32EDE2F3-3A9C-4025-82E6-64767E2320BAQ27334472-1617B3D9-2779-4105-8A18-BE971D6D0784Q27498993-DE267DEC-3D38-4611-8E65-ECB1AD9B2D5AQ27691820-AC6885FE-C162-4477-A0C0-CC090AFC5B5EQ28072237-45796026-67DA-44AB-99D2-6FC2EF82A8DCQ28274003-7CCC48C3-D3A1-4EBD-8296-9F336C17B1BFQ28391948-50D910DF-01C7-460E-B117-075F5761B377Q29248581-6DF5A956-196F-4EBC-B401-114124709EFCQ29248766-C58D7CF3-ECAB-4B0A-934F-F8DE08586807Q30426968-12F676F6-7BBC-48C1-AB01-C10E3AC1F5C4Q30437914-413AAFFA-C6CC-423B-B7F0-385F90DAF4CAQ30530945-2428A389-83DB-41A2-BAA8-450B25C17E9EQ30834004-A5F7C156-205B-4AD6-984B-77441C5DB797Q33458331-75939AD1-7CC6-424B-997E-DA3A8D7CAF7DQ33614987-2AB31951-3752-4865-AFA4-5641E4C1265CQ33624586-C3241E47-BFE9-4E11-AA17-C0FD5A9185E1Q33720370-DC2B0A47-92C3-4332-9930-0FE293332402Q33730187-CB627528-2E98-4FB2-A4D9-6DE09F7EE9AAQ33809556-A10B0BE5-997F-4787-8B71-98C2440637FCQ33831774-35E350E2-F26A-4F82-B47F-0DF246247FFEQ33892289-0240E6E9-C30A-4912-92D4-511F13351F48Q33959395-968F0751-85CC-4818-8C5F-0AC3B6C5AD8DQ33985904-9728CB5F-C962-4C59-9449-3726301DAA38Q34038205-F923145F-2499-4A5B-A083-7697D34EED3DQ34043950-D1080D5F-4347-4D37-B9C8-C2BE26F86986Q34098196-23848583-1FBB-458B-8DB4-9A1645352ED7Q34581918-B0AF3843-C1C8-4682-ACCE-6B10BE5E4A14Q34795840-87748DAB-BD00-4086-80E8-6E32D6F2324DQ35108302-D28BED2F-E0B0-46F9-A11D-6331763DC6BDQ35135962-F0F80A7B-ADD3-400B-8796-3A34339A1F85Q35271805-A22CFE56-DE90-4A6E-85BF-E7FC70BE092D
P2860
Microglial activation in presymptomatic Huntington's disease gene carriers.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Microglial activation in presymptomatic Huntington's disease gene carriers.
@en
Microglial activation in presymptomatic Huntington's disease gene carriers.
@nl
type
label
Microglial activation in presymptomatic Huntington's disease gene carriers.
@en
Microglial activation in presymptomatic Huntington's disease gene carriers.
@nl
prefLabel
Microglial activation in presymptomatic Huntington's disease gene carriers.
@en
Microglial activation in presymptomatic Huntington's disease gene carriers.
@nl
P50
P356
P1433
P1476
Microglial activation in presymptomatic Huntington's disease gene carriers.
@en
P2093
Paola Piccini
P304
P356
10.1093/BRAIN/AWM044
P407
P577
2007-03-30T00:00:00Z